NCT00177307 Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer Status COMPLETED Phase PHASE2
NCT00177281 Safety Study of S-CKD602 in Patients With Advanced Malignancies Status COMPLETED Phase PHASE1
NCT00177255 A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers Status TERMINATED Phase PHASE2
NCT00177242 Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma Status COMPLETED Phase PHASE2
NCT00173290 Cytokine Regulation of Natural Killer Receptors in Inhibiting Activated T Cell Function Status UNKNOWN Phase N/A
NCT00171964 Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions Status COMPLETED Phase PHASE4
NCT00168181 Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients Status COMPLETED Phase PHASE3
NCT00167648 Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer Status COMPLETED Phase PHASE2
NCT00161187 Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Status COMPLETED Phase PHASE1
NCT00153868 A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer Status COMPLETED Phase PHASE4
NCT00152867 Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy Status COMPLETED Phase PHASE3
NCT00148525 The Study of Automated Telephone Programs for the Maintenance of Dietary Change Status COMPLETED Phase PHASE1
NCT00144131 Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy Status COMPLETED Phase PHASE2
NCT00135577 Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects Status COMPLETED Phase PHASE2
NCT00135317 AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies Status COMPLETED Phase PHASE3